Thursday July 25, 2024

Discover more about the latest developments in our research and advocacy efforts.

• The Leukaemia Foundation recently prepared three separate submissions supporting greater, more affordable access to three therapeutics for multiple myeloma, follicular lymphoma and acute lymphoblastic leukaemia (ALL).
• If subsidised, these treatments may give eligible patients better access to additional treatment options.
• These separate submissions are provided to the relevant bodies making recommendations on whether drugs/therapies are subsidised (MSAC/PBAC).
• Without subsidy, these can be very expensive, and for some, unaffordable. Equitable, affordable access to treatment is therefore about helping to save lives, and is also about health system equity.
• In an effort to amplify the voice of Australians living with blood cancer, these submissions include first-hand accounts and experiences from patients who have either been treated with the drug as part of a clinical trial, or had relevant experience with a similar treatment.